In This Article:
Champions Oncology, Inc. CSBR will report third-quarter fiscal 2019 results.
In the last reported quarter, Champions Oncology witnessed a negative surprise of 25%.
Shares of the company have surged 46.3% so far this year.
Let’s see how things are shaping up for this quarter to be reported.
Factors at Play
Champions Oncology develops technology solutions and services to customize the development and use of oncology drugs. The company does not have any approved products in its portfolio.
It has two new services, namely Ex Vivo platform and pre-approved Clinical Flow Cytometry. The EX VIVO platform and services enable the company’s large tumor bank to support large screening studies and assist customers with early preclinical work.
Notably, the already launched Ex Vivo services are yielding promising results and the company expects the same from the recently launched Ex Vivo platform as well.
Earlier, on second-quarter fiscal 2019 conference call, Champions Oncology stated that it is focused on expanding its human Clinical Flow Cytometry platform beyond preclinical studies. Back then, management confirmed that it will share some preliminary results on the same over the next two quarters and expect to start generating revenues from Cytometry services only toward the end of the next fiscal year. We expect an update on that front during the upcoming earnings call.
Surprise History
Champions Oncology’s performance over the last three reported quarters has been mixed. The company’s earnings surpassed expectations once, missed on another occasion and fell in line with estimates in another quarter, the average positive surprise being 125.00%.
Earnings Whispers
Our proven model does not conclusively show that Champions Oncology is likely to beat estimates this reporting cycle. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. But that is not the case here as you will see below.
Earnings ESP: Champions Oncology has an Earnings ESP of 0.00% as the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at 3 cents each. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Champions Oncology currently has a Zacks Rank #5 (Strong Sell). We caution against stocks with a Zacks Rank #4 (Sell) or 5 going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Champions Oncology, Inc. Price and EPS Surprise
Champions Oncology, Inc. Price and EPS Surprise | Champions Oncology, Inc. Quote